Been looking at an interesting corner of the biotech market that doesn't get enough attention - psychedelic-assisted therapy stocks. While cannabis got all the regulatory wins, there's a whole other category of compounds like psilocybin, ketamine, and LSD that are showing real promise for treating depression and other mental health issues. Some solid clinical data is backing this up too.

The sector had its moment in the sun a couple years back when several of these companies went public, but most have taken a serious beating since then. That dip might be worth paying attention to though, especially if you're thinking about the long-term potential of mushroom stocks to buy and hold.

Let me break down three plays in this space worth considering:

First up is Atai Life Sciences. This one's the broader play - they're working on multiple psychedelic-derived compounds including ketamine, DMT, and psilocybin. Their most interesting project is COMP360 (co-developed with another pharma company), which just entered Phase 3 trials. The company's taking on a lot of financial burden with this diversified approach, but that actually increases the odds of getting something approved by the FDA. Currently trading at a massive discount from its IPO price, so any positive news on their pipeline could move the needle fast.

Then there's Compass Pathways. This one's more focused - they're basically all-in on psilocybin therapy through that COMP360 drug I mentioned. For investors, this means you're making a direct bet on one specific FDA approval. Their Phase IIb data showed that 20% of treatment-resistant depression patients saw sustained improvement by week 12. That's actually pretty solid when you remember these are patients who didn't respond to traditional antidepressants. This kind of focused approach appeals to investors who want a clear catalyst.

Lastly, Cybin is the riskier play. They're developing multiple psilocybin-based therapies and trading in penny stock territory. The company's still in pure research mode with no revenue yet, just losses for the past several quarters. But here's the thing - their deuterated psilocybin program got FDA breakthrough therapy designation after Phase II success for major depressive disorder. That status matters because it could accelerate development. If you're looking at mushroom stocks to buy for potential upside, this one has the highest risk but maybe the highest reward if their programs work out.

The broader takeaway here is that we're probably still in the early innings of psychedelic medicine becoming mainstream. The regulatory path is clearer now than it was a few years ago, and the clinical data keeps getting better. These stocks got crushed in the selloff, so there might be real opportunity if you believe in the long-term thesis. Just remember these are all pre-revenue biotech plays, so they come with execution risk. But that's also where the real returns typically come from in this sector.